Received Sep 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE details reported; their first dose of GARDASIL (unknown if 2-, 4-, or 9- valent vaccine) about 10 years ago and administered their second dose of GARDASIL 9 on 04/30/2025; This spontaneous report was received from a pharmacist, concerning to a 35-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date in 2015 (10 years ago), the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) or with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL), 1 dosage form, total (route, lot# and expiration date not provided. On 30-Apr-2025, received the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), 1 dosage form, total, (route, lot # and expiration date were not reported). All as prophylaxis. Since doses were administered within more than 13 months as recommended, inappropriate schedule of product administration on 30-Apr-2025. No additional AE details reported (No adverse event).